YOUR BUSINESS AUTHORITY
Springfield, MO
YOUR BUSINESS AUTHORITY
Springfield, MO
Johnson & Johnson will pay $2.2 billion to settle charges that the company marketed the drugs Risperdal, Invega and Natrector for unapproved uses and paid kick-backs to doctors and nursing homes, according to CNNMoney.
Johnson & Johnson will plead guilty to a misdemeanor misbranding charge stemming from the marketing charges.
Risperdal is approved by the Federal Drug Administration to treat schizophrenia, but Johnson & Johnson reportedly marketed the drug to doctors and nursing homes as a treatment for elderly patients with dementia. Invega was marketed as safe for elderly patients when the FDA hadn't approved it as such. Natrecor was marketed as a safe treatment for individuals with less severe heart conditions than what the drug was approved for by the FDA.
As part of the settlement, Johnson & Johnson - and subsidiaries Janssen Pharmaceuticals and Scios - will pay $167.7 million in whistleblower payouts, as well as payments to the federal government and several states.
Read more from CNNMoney.
This installment of Springfield Business Journal’s Architects & Engineers Project Report showcases 26 endeavors by area design and engineering professionals.
Longtime employee sues Ozarks Tech, alleges retaliation
Cavender’s opens hat shop in southeast Springfield
Eric Schmitt introduces Modern Skies Act
Caterpillar to acquire John Fabick Tractor Co.
Springfield airport to cut the ribbon on $35M in construction projects
Legacy Bank accused in lawsuit of failing to protect customers in data breach